Results 161 to 170 of about 18,455 (220)

Peptide Receptor Radionuclide Therapy Improves Survival in Patients Who Progress After Resection of Gastroenteropancreatic Neuroendocrine Tumors. [PDF]

open access: yesAnn Surg Oncol
Borbon LC   +11 more
europepmc   +1 more source

The South Australian <sup>177</sup>Lu-DOTATATE peptide receptor radionuclide therapy service: an 11-year review of toxicity, health-related quality of life, and survival. [PDF]

open access: yesESMO Gastrointest Oncol
Altus LM   +11 more
europepmc   +1 more source

Peptide Receptor Radionuclide Therapy in Advanced Refractory Meningiomas: Efficacy and Toxicity in a Long Follow-up. [PDF]

open access: yesJ Nucl Med
Severi S   +21 more
europepmc   +1 more source

Outcome of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy in Progressive Metastatic Neuroendocrine Tumors from a Tertiary Care Center. [PDF]

open access: yesIndian J Endocrinol Metab
Mathew D   +7 more
europepmc   +1 more source

Clinical characteristics and treatment patterns of patients with gastroenteropancreatic neuroendocrine neoplasia in Germany receiving peptide receptor radionuclide therapy: A real-world data registry-based study. [PDF]

open access: yesMedicine (Baltimore)
von Hessert-Vaudoncourt C   +10 more
europepmc   +1 more source

Safety and Efficacy of Peptide Receptor Radionuclide Therapy (PRRT) Following Bland Embolization for Metastatic Neuroendocrine Tumors. [PDF]

open access: yesCancers (Basel)
Alayli A   +9 more
europepmc   +1 more source

The Safety and Efficacy of Peptide Receptor Radionuclide Therapy for Gastro-Entero-Pancreatic Neuroendocrine Tumors: A Single Center Experience. [PDF]

open access: yesCurr Oncol
Piscopo L   +10 more
europepmc   +1 more source

Safety and efficacy of peptide receptor radionuclide therapy in neuroendocrine tumors: A single center experience. [PDF]

open access: yesPLoS One
Sukrithan V   +19 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy